MOU Signed for World First Cannabis Trial for Children with Epilepsy
The MOU will facilitate:
- A world first, phase 2 clinical trial for a novel product, phytocannabinoid cannibidivarin (CBDV) in children;
- A phase 4 clinical trial of EpidiolexÒ based on phase 3 studies;
- A compassionate access scheme for EpidiolexÒ; and
- Provision for NSW to host future clinical trials of GW Pharmaceutical products.
The NSW Government is providing $3.5 million to the Sydney Children's Hospital Network (SCHN) to lead this world first, phase 2 clinical trial of CBDV in children, which will commence in 2016.
For more information:
phone: Cannabis Clinical Trials Helpline is 1800 217 257.